Hi John,
The Obesity Action Coalition (OAC) is excited to offer an opportunity for members to share their voice and lived experience in an important advisory board discussion. One of our partners is seeking valuable insights from OAC members who have experience with obesity and/or Fatty Liver Disease (also called Metabolic Dysfunction-Associated Steatohepatitis, or MASH). There are five advisory boards planned for 2025, and one of them will meet in person on June 11th and 12th. All travel and lodging expenses will be covered. Read on for more details about the advisory board, including the objectives and inclusion criteria.
Objectives: -
Understanding Obesity and MASH Treatment Acceptance: Gain insights into what factors influence a patient's acceptance of obesity treatment and their treatment for MASH. -
Clinical Trial Data Insights: Collect feedback on a phase 2 clinical trial, focusing on how patients understand trial results when explained in simple, non-technical language. -
Knowledge of Treatment Mechanisms: Learn more about patients' understanding of certain treatment mechanisms, including glucagon-like-peptide (GLP), gastric inhibitory polypeptide (GIP) and glucagon receptor (GCGR) actions. Inclusion Criteria: - Between the ages of 18-75.
- People living with obesity and/or Fatty Liver Disease/MASH.
- We would like to ensure the advisory board is diverse so if you are comfortable providing your race and gender that would be greatly appreciated.
While this is not an official OAC opportunity, we are happy to help connect interested members to this opportunity. If you have are interested in taking part in the advisory board, please email your interest to [email protected] by Monday, March 17th. |
|
